**Participant flow**

Men or women

Age 18-70y

No GSV reflux

Willing participate

History DVT

Pregnancy

Poor general health

anticoagulation

NSAI´s

Not willing to use compression

Fail visit

Fail medication or compression

Abandon study

Sulodexide oral dose 500 LRU-day

1 month

3 months

|  |  |  |
| --- | --- | --- |
| **Inclusion criteria** | **Exclusion criteria** | **Elimination criteria** |
| Age 18 - 65 years.Telangiectasia, reticular, or varicose veins in lower limbs.Candidate for sclerotherapy.BMI 20 – 40 kg/m2.Fitzpatrick skin tone I – V.Sign a consent to participate. | Acute Thrombosis.History of Deep vein thrombosis.Deep vein reflux. Saphenous vein reflux.Pregnancy.Bed confinement.Long term use of steroidal or nonsteroidal anti-inflammatory drugs (corticoids, methotrexate, etc.).Severe leg edema.Concomitant severe disease (heart, liver, renal, etc.).Local skin infection.Severe skin scaring.Chronic arterial disease.Fitzpatrick skin tone VI.Thrombophilia.Small area to treat (equivalent to < ¼ of the leg superficial area). | Voluntary study withdraws.Non-compliant with elastic compression.Voluntary stop taking sulodexide.Lost to follow-up.Pregnancy detection during the study period.Severe disease detected during the study period. |

*Inclusion, exclusion and elimination criteria*

**Baseline Characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| Patients Characteristics  | Study group(n=359) | Control group (n=361) | P value |
| Sex *Female, No., %* *Male, No., %*Age, mean, yearsBMI, mean, kg/m2Fitzpatrick skin tone I, n, % II, n, % III, n, % IV, n, % V, n, %Type of veins treated Telangiectasia (>1mm), % Reticular (1-3mm), % Varicose (>3mm), % |  339 (94.4)20 (6.6)41 (SD=12.4)31.94 (SD=4.5)10 (2.7)29 (8)131 (36.4)146 (40.6)42 (11.6)858764 | 337 (93.3)24 (6.7)42 (SD 12.8)30.96 (SD=4.8)15 (4.1)34 (9.4)124 (34.3)138 (38.2)47 (13)838567 | NSNSNSNSNSNSNSNSNSNSNSNS |

Population characteristics. SD: Standard deviation, BMI: Body mass index, NS: Not Significant, n: Number patients. Significance set at p< 0.05 using student t-test

**Outcome Measures**

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment Outcome Results | Study groupN= 320 (1-month)N= 312 (3-months) | Control groupN= 318 (1-month)N= 297 (3-month) | P value |
| Presence hyperpigmentation 1 month, No, % 3 months, No, %Total area affected 1 month, % 3 months, %Skin-tone increase 1 month, %, SD 3 months, %, SDMajor bleeding 1 month 3 monthsTherapeutic vein disappearance 1 month, % 3 months, % | 28 (8.7)16 (5.1) 10.7 (7.9)4.7 (6.2)17 (7.9)6.9 (8.8)004676 | 47 (14.8)31 (10.4)18.2 (9.1)8.6 (9.5)25 (9.8)9.5 (10.6)004873 |  0.01 0.02<0.01 0.04 0.02 NS NS NSNSNS |

Treatment outcome results. SD: standard deviation. Significance set at P< 0.05 using Chi square test and Student t-test. Relative risk reduction: 41%. Absolute risk reduction: 6.1%.

**Adverse Events**

|  |  |  |  |
| --- | --- | --- | --- |
| **Adverse event** | **Study group** | **Control group** |  |
| Headache, nGastrointestinal, nMajor bleeding, nNeed to suspend medicationNeed use otherMedication for leg pain At 1 month, n At 3 months, nNeed thrombectomy   | 5800709 | 760028011 |  |
| **Excluded participant** At 1 month, n At 3 month, n totalLost to follow-up, nNC compression, nNC medication, n | 3984722179 | 432164292213 |  |

*NC Non- Compliant*